Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
CardioNerds @AHA23: AZALEA-TIMI 71: Abelcibab Vs Rivaroxaban in Patients with AF
Author(s): Naima Maqsood , Christian Ruff Added: 2 years ago
AHA 23 - Dr Naima Maqsood, CardioNerds ambassador (Temple University Hospital, US) interviews Dr Christian Ruff (Brigham and Women's Hospital, US) on the late-breaking findings from the AZALEA-TIMI 71 randomized trial (Anthos Theraputics, Inc).AZALEA-TIMI 71 aimed to evaluate the bleeding profile of abelacimab as compared to rivaroxaban in patients with atrial fibrillation who are at moderate to… View more

Anticoagulation

Electrophysiology & Arrhythmia
AHA 25: The OCEAN Trial
Author(s): Atul Verma Added: 5 months ago
AHA Scientific Sessions 2025 - Dr Atul Verma (McGill University Health Centre, Montreal, CA) joins us to share outcomes from OCEAN (NCT02168829). The prospective, open-label, randomised trial aimed to investigate ongoing oral anticoagulation with rivaroxaban 15 mg daily compared to antiplatelet therapy in patients with clinical stroke risk factors at least one year post-successful catheter… View more

Anticoagulation

Electrophysiology & Arrhythmia
Secondary Prevention of Atherosclerotic Cardiovascular Disease
Author(s): Madelyn Hurwitz , Olayinka J Agboola , Abhishek Gami , et al Added: 11 months ago

Prevention & Chronic Conditions
AHA 2023 Late-Breaking Science Lineup Revealed
Added: 2 years ago Source:  AHA
AUTHOR: Jordan RanceThe American Heart Association has announced eight late-breaking science sessions to be presented in Philadelphia from November 10th to November 13th. AHA is focussed on innovation in cardiovascular disease for scientists, clinicians, researchers and other healthcare professionals.Among the event’s highlights are eight late-breaking trial sessions, as listed below.Watch our… View more